Astria Therapeutics (ATXS) Competitors $3.98 -0.12 (-2.93%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATXS vs. OCUL, IOVA, SNDX, WVE, COLL, ELVN, DYN, GPCR, ETNB, and CMRXShould you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Ocular Therapeutix (OCUL), Iovance Biotherapeutics (IOVA), Syndax Pharmaceuticals (SNDX), Wave Life Sciences (WVE), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), 89bio (ETNB), and Chimerix (CMRX). These companies are all part of the "pharmaceutical products" industry. Astria Therapeutics vs. Ocular Therapeutix Iovance Biotherapeutics Syndax Pharmaceuticals Wave Life Sciences Collegium Pharmaceutical Enliven Therapeutics Dyne Therapeutics Structure Therapeutics 89bio Chimerix Astria Therapeutics (NASDAQ:ATXS) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, media sentiment, profitability and dividends. Does the MarketBeat Community believe in ATXS or OCUL? Astria Therapeutics received 130 more outperform votes than Ocular Therapeutix when rated by MarketBeat users. Likewise, 73.15% of users gave Astria Therapeutics an outperform vote while only 70.27% of users gave Ocular Therapeutix an outperform vote. CompanyUnderperformOutperformAstria TherapeuticsOutperform Votes57273.15% Underperform Votes21026.85% Ocular TherapeutixOutperform Votes44270.27% Underperform Votes18729.73% Which has more volatility and risk, ATXS or OCUL? Astria Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Does the media refer more to ATXS or OCUL? In the previous week, Ocular Therapeutix had 10 more articles in the media than Astria Therapeutics. MarketBeat recorded 10 mentions for Ocular Therapeutix and 0 mentions for Astria Therapeutics. Astria Therapeutics' average media sentiment score of 1.87 beat Ocular Therapeutix's score of 0.73 indicating that Astria Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Astria Therapeutics Very Positive Ocular Therapeutix Positive Which has stronger valuation & earnings, ATXS or OCUL? Astria Therapeutics has higher earnings, but lower revenue than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAstria TherapeuticsN/AN/A-$72.89M-$1.67-2.38Ocular Therapeutix$63.72M17.89-$80.74M-$1.26-5.69 Do analysts prefer ATXS or OCUL? Astria Therapeutics currently has a consensus target price of $26.60, indicating a potential upside of 568.34%. Ocular Therapeutix has a consensus target price of $16.38, indicating a potential upside of 128.38%. Given Astria Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Astria Therapeutics is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Ocular Therapeutix 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Is ATXS or OCUL more profitable? Astria Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -283.74%. Astria Therapeutics' return on equity of -43.58% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Astria TherapeuticsN/A -43.58% -29.36% Ocular Therapeutix -283.74%-45.18%-30.87% Do insiders and institutionals hold more shares of ATXS or OCUL? 99.0% of Astria Therapeutics shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 2.9% of Astria Therapeutics shares are held by insiders. Comparatively, 3.5% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryAstria Therapeutics beats Ocular Therapeutix on 12 of the 18 factors compared between the two stocks. Remove Ads Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXS vs. The Competition Export to ExcelMetricAstria TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$224.61M$6.26B$5.29B$7.35BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-1.906.6921.6517.68Price / SalesN/A222.70371.0992.89Price / CashN/A65.6738.1534.64Price / Book1.205.776.373.94Net Income-$72.89M$142.01M$3.20B$247.45M7 Day Performance-2.45%2.88%1.79%0.48%1 Month Performance-38.29%-13.93%-9.41%-7.08%1 Year Performance-64.14%-12.36%9.61%-0.35% Astria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXSAstria Therapeutics2.4519 of 5 stars$3.98-2.9%$26.60+568.3%-62.4%$224.61MN/A-1.9030Positive NewsOCULOcular Therapeutix3.4384 of 5 stars$6.30-0.9%$16.38+159.9%-3.5%$1.00B$63.72M-4.77230Gap DownIOVAIovance Biotherapeutics4.227 of 5 stars$3.03+1.0%$20.25+568.3%-72.8%$993.47M$164.07M-2.03500Analyst ForecastNews CoverageHigh Trading VolumeSNDXSyndax Pharmaceuticals3.3452 of 5 stars$11.01-2.1%$36.20+228.8%-47.6%$947.34M$23.68M-3.03110Positive NewsGap UpWVEWave Life Sciences4.1587 of 5 stars$5.80-3.8%$22.60+289.7%+9.4%$890.22M$108.30M-5.23240Short Interest ↑Analyst RevisionGap DownCOLLCollegium Pharmaceutical4.1502 of 5 stars$27.38-2.7%$43.60+59.2%-22.8%$879.77M$631.45M11.80210Gap DownELVNEnliven Therapeutics2.5699 of 5 stars$17.87-4.4%$38.75+116.8%-14.5%$875.70MN/A-9.4150Gap DownDYNDyne Therapeutics3.5776 of 5 stars$7.49-9.5%$47.46+533.7%-69.1%$847.28MN/A-2.10100GPCRStructure Therapeutics2.5837 of 5 stars$14.31-5.4%$81.29+468.0%-49.8%$820.58MN/A-19.34136News CoverageETNB89bio2.5898 of 5 stars$5.49-4.9%$27.56+401.9%-36.2%$801.45MN/A-1.8940Short Interest ↑High Trading VolumeCMRXChimerix2.7397 of 5 stars$8.52-0.1%$8.53+0.2%+834.8%$799.21M$212,000.00-9.0690Analyst ForecastPositive News Remove Ads Related Companies and Tools Related Companies Ocular Therapeutix Competitors Iovance Biotherapeutics Competitors Syndax Pharmaceuticals Competitors Wave Life Sciences Competitors Collegium Pharmaceutical Competitors Enliven Therapeutics Competitors Dyne Therapeutics Competitors Structure Therapeutics Competitors 89bio Competitors Chimerix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATXS Stock Free ATXS Stock Alerts